AMP Amphion Innovations Plc

 

TIDMAMP 
 
 
Amphion Innovations PLC 
06 October 2009 
 
? 
Amphion Innovations Partner Company, WellGen, Achieves Important Milestone in 
Development of Medical Food for Diabetes 
London and New York, October 6, 2009 - Amphion Innovations plc (LSE: AMP) 
("Amphion"), the developer of medical and technology businesses, today announces 
that, Amphion Partner Company, WellGen Inc., has, through pre-clinical trials, 
demonstrated that its propriety black tea concentrate significantly improves 
glucose control. WellGen  theaflavin-rich black tea concentrate, already known 
to be anti-inflammatory, favorably affected critical biomarkers of diabetes. 
The recently completed study examined whether WellGen black tea concentrate 
affected measures indicative of the control of diabetes such as fasting glucose, 
postprandial glucose, and HbA1c. These are all important measures of glucose 
control. HbA1c reflects the average concentration of glucose in a subject's 
blood over a prolonged time. Secondarily, the study compared the effect of a 
diet including WellGen black tea concentrate versus a single daily dose of 
metformin, the first-line pharmaceutical intervention in the treatment of 
diabetes. 
The results of this study demonstrated that a diet containing WellGen's 
proprietary nutraceutical significantly improved HbA1c, with a larger beneficial 
effect than the pharmaceutical metformin. Additionally, WellGen black tea 
concentrate lowered fasting glucose and significantly reduced postprandial 
glucose concentrations. 
Based on this important finding and other supportive data, WellGen is planning 
human clinical studies to support a medical food for diabetes using WellGen 
black tea concentrate. The human study will examine glucose measures and markers 
of inflammation in patients with type 2 diabetes. 
WellGen, Inc. studies natural products with anti-inflammatory properties which 
work at the level of gene expression under its nutrigenomics research programme. 
The Company had predicted a favourable effect on diabetes measures using its 
Alignomx(TM) model. WellGen's theaflavin-rich black tea concentrate is the first 
in a pipeline of natural products to go through the company's research programme 
that applies biotechnology and pharmaceutical practices to discover and develop 
medical food products. 
For further information please contact 
+----------------------------------------------------+----------------------------------------+ 
| Amphion Innovations plc                            |                                        | 
+----------------------------------------------------+----------------------------------------+ 
| Charlie Morgan, Director of Communications         | +1 (212) 210 6224                      | 
+----------------------------------------------------+----------------------------------------+ 
|                                                    |                                        | 
+----------------------------------------------------+----------------------------------------+ 
| WellGen, Inc.                                      |                                        | 
+----------------------------------------------------+----------------------------------------+ 
| Patricia Lucas-Schnarre, Vice President, Marketing | +1 (732) 565 3890 x4403                | 
+----------------------------------------------------+----------------------------------------+ 
| Cardew Group                                       |                                        | 
+----------------------------------------------------+----------------------------------------+ 
| Tim Robertson/ Jamie Milton/ Matthew Law           | +44 20 7930 0777                       | 
+----------------------------------------------------+----------------------------------------+ 
| Charles Stanley (Nominated Adviser)                |                                        | 
+----------------------------------------------------+----------------------------------------+ 
| Mark Taylor/ Freddy Crossley                       | +44 20 7149 6000                       | 
+----------------------------------------------------+----------------------------------------+ 
 
 
About Amphion Innovations plc 
Amphion (LSE: AMP) builds shareholder value in high growth companies in the 
medical and technology sectors, by using a focused, hands-on company building 
approach, based on decades of experience in both the US and UK.   Amphion has 
significant shareholding in 10 Partner Companies developing proven technologies 
targeting substantial commercial marketplaces, each in excess of $1 billion. 
Each Partner Company is chosen with the goal of achieving an exit valuation in 
excess of $100 million. 
On the web: www.amphionplc.com 
 
 
About WellGen, Inc. 
WellGen, Inc., based in North Brunswick, N.J., is a biotechnology company at the 
crossroads of foods and pharmaceuticals. Using the science of nutrigenomics, the 
company has developed Alignomx(TM), a proprietary bioinformatics model that uses 
gene expression data to determine optimal therapeutic areas for WellGen's 
pipeline of proprietary natural products. Through its in-house expertise in 
nutrigenomics and natural product chemistry, WellGen is developing proprietary 
medical foods and has additionally identified several opportunities in the 
functional food and beverage and dietary supplement markets. 
On the web: www.wellgen.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAMFBRTMMAMMAL 
 

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024